Elicio Therapeutics, Inc. Proceeds from Stock Options Exercised
Elicio Therapeutics, Inc. (ELTX) reported Proceeds from Stock Options Exercised of $117.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2026-08-13
- Elicio Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2026-06-30 was $17.00K, a 66.00% decline year-over-year.
- Elicio Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2026-03-31 was $100.00K, a 1328.57% increase year-over-year.
- Elicio Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2025-12-31 was $4.00K, a 20.00% decline year-over-year.
- Elicio Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2025-09-30 was $88.00K, a 319.05% increase year-over-year.
- Elicio Therapeutics, Inc. proceeds from stock options exercised for fiscal 2025 was $149.00K, a 282.05% increase from fiscal 2024.
- Elicio Therapeutics, Inc. proceeds from stock options exercised for fiscal 2024 was $39.00K, a 69.29% decline from fiscal 2023.
- Elicio Therapeutics, Inc. proceeds from stock options exercised for fiscal 2023 was $127.00K, a 54.88% increase from fiscal 2022.
- Elicio Therapeutics, Inc. proceeds from stock options exercised for fiscal 2022 was $82.00K, a 91.63% decline from fiscal 2021.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 6 month as first filed | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 9 month as first filed | Proceeds from Stock Options Exercised 12 month | Proceeds from Stock Options Exercised 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $17.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $117.00K 10-Q · filed 2026-08-13 | $121.00K derived: sum of 3 quarters · filed 2026-08-13 | $209.00K derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $100.00K 10-Q · filed 2026-05-11 | $104.00K derived: sum of 2 quarters · filed 2026-05-11 | $192.00K derived: sum of 3 quarters · filed 2026-05-11 | $242.00K derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $92.00K derived: sum of 2 quarters · filed 2026-03-12 | $142.00K derived: sum of 3 quarters · filed 2026-08-13 | $149.00K 10-K · filed 2026-03-12 | |||
| 2025-09-30 | $88.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $138.00K derived: sum of 2 quarters · filed 2026-08-13 | $145.00K 10-Q · filed 2025-11-13 | $150.00K derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $50.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $57.00K 10-Q · filed 2026-08-13 | $62.00K derived: sum of 3 quarters · filed 2026-08-13 | $83.00K derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $7.00K 10-Q · filed 2026-05-11 | $12.00K derived: sum of 2 quarters · filed 2026-05-11 | $33.00K derived: sum of 3 quarters · filed 2026-05-11 | $46.00K derived: sum of 4 quarters · filed 2026-05-11 | |||
| 2024-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $26.00K derived: sum of 2 quarters · filed 2026-03-12 | $39.00K derived: sum of 3 quarters · filed 2026-03-12 | $39.00K 10-K · filed 2026-03-12 | |||
| 2024-09-30 | $21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $34.00K derived: sum of 2 quarters · filed 2025-11-13 | $34.00K 10-Q · filed 2025-11-13 | $34.00K derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | $13.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $13.00K 10-Q · filed 2025-08-07 | $13.00K derived: sum of 3 quarters · filed 2025-08-07 | $73.00K derived: sum of 4 quarters · filed 2025-08-07 | |||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-13 | $0.00 derived: sum of 2 quarters · filed 2025-05-13 | $60.00K derived: sum of 3 quarters · filed 2025-05-13 | $87.00K derived: sum of 4 quarters · filed 2025-05-13 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $60.00K derived: sum of 2 quarters · filed 2025-03-31 | $87.00K derived: sum of 3 quarters · filed 2025-03-31 | $127.00K 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $60.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $87.00K derived: sum of 2 quarters · filed 2024-11-13 | $127.00K 10-Q · filed 2024-11-13 | $192.00K derived: sum of 4 quarters · filed 2024-11-13 | |||
| 2023-06-30 | $27.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $67.00K 10-Q · filed 2024-08-13 | $132.00K derived: sum of 3 quarters · filed 2024-08-13 | $71.00K derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | $40.00K 10-Q · filed 2024-05-15 | $105.00K derived: sum of 2 quarters · filed 2024-05-15 | $44.00K derived: sum of 3 quarters · filed 2024-05-15 | $122.00K derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | $65.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $4.00K derived: sum of 2 quarters · filed 2024-03-29 | $82.00K derived: sum of 3 quarters · filed 2024-03-29 | $82.00K 10-K · filed 2024-03-29 | $0.00 10-K · filed 2023-03-17 | ||
| 2022-09-30 | -$61.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $17.00K derived: sum of 2 quarters · filed 2023-11-13 | $17.00K 10-Q · filed 2023-11-13 | $0.00 10-Q · filed 2022-11-14 | $131.00K derived: sum of 4 quarters · filed 2023-11-13 | ||
| 2022-06-30 | $78.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $78.00K 10-Q · filed 2023-08-14 | $0.00 10-Q · filed 2022-08-15 | $192.00K derived: sum of 3 quarters · filed 2023-08-14 | $978.00K derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-16 | $114.00K derived: sum of 2 quarters · filed 2023-03-17 | $900.00K derived: sum of 3 quarters · filed 2023-03-17 | $979.00K derived: sum of 4 quarters · filed 2023-03-17 | |||
| 2021-12-31 | $114.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $900.00K derived: sum of 2 quarters · filed 2023-03-17 | $979.00K derived: sum of 3 quarters · filed 2023-03-17 | $980.00K 10-K · filed 2023-03-17 | |||
| 2021-09-30 | $786.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $865.00K derived: sum of 2 quarters · filed 2022-11-14 | $866.00K 10-Q · filed 2022-11-14 | $875.00K derived: sum of 4 quarters · filed 2022-11-14 | |||
| 2021-06-30 | $79.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $80.00K 10-Q · filed 2022-08-15 | $89.00K derived: sum of 3 quarters · filed 2022-08-15 | $126.00K derived: sum of 4 quarters · filed 2022-08-15 | |||
| 2021-03-31 | $1.00K 10-Q · filed 2022-05-16 | $10.00K derived: sum of 2 quarters · filed 2022-05-16 | $47.00K derived: sum of 3 quarters · filed 2022-05-16 | $47.00K derived: sum of 4 quarters · filed 2022-05-16 | |||
| 2020-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $46.00K derived: sum of 2 quarters · filed 2022-03-30 | $46.00K derived: sum of 3 quarters · filed 2022-03-30 | $47.00K 10-K · filed 2022-03-30 | |||
| 2020-09-30 | $37.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $37.00K derived: sum of 2 quarters · filed 2021-11-12 | $38.00K 10-Q · filed 2021-11-12 | ||||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $1.00K 10-Q · filed 2021-08-12 | |||||
| 2020-03-31 | $1.00K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |